

Misael Uribe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5513347/publications.pdf>

Version: 2024-02-01

141
papers

5,771
citations

76322

40
h-index

88628

70
g-index

148
all docs

148
docs citations

148
times ranked

7475
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Oxidative Stress and Molecular Changes in Liver Fibrosis: A Review. <i>Current Medicinal Chemistry</i> , 2012, 19, 4850-4860.	2.4	438
2	The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus. <i>Hepatology</i> , 2013, 58, 325-336.	7.3	326
3	Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 509-518.	3.7	231
4	The Role of the Gut Microbiota in Bile Acid Metabolism. <i>Annals of Hepatology</i> , 2017, 16, S21-S26.	1.5	210
5	Bariatric surgery for non-alcoholic steatohepatitis in obese patients. <i>The Cochrane Library</i> , 2010, , CD007340.	2.8	204
6	Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens. <i>Annals of Hepatology</i> , 2010, 9, 402-409.	1.5	192
7	Current concepts in the pathogenesis of nonalcoholic fatty liver disease. <i>Liver International</i> , 2007, 27, 423-433.	3.9	154
8	Metabolic syndrome as a risk factor for gallstone disease. <i>World Journal of Gastroenterology</i> , 2005, 11, 1653.	3.3	150
9	Effect of Ezetimibe on the Prevention and Dissolution of Cholesterol Gallstones. <i>Gastroenterology</i> , 2008, 134, 2101-2110.	1.3	144
10	Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. <i>The Cochrane Library</i> , 2010, , CD002907.	2.8	144
11	The prevalence of nonalcoholic fatty liver disease in the Americas. <i>Annals of Hepatology</i> , 2014, 13, 166-178.	1.5	122
12	Role of bioactive fatty acids in nonalcoholic fatty liver disease. <i>Nutrition Journal</i> , 2015, 15, 72.	3.4	96
13	Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2008, 7, 212-220.	1.5	91
14	Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. <i>Annals of Hepatology</i> , 2005, 4, 52-55.	1.5	84
15	A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. <i>Nutrition Journal</i> , 2013, 12, 74.	3.4	84
16	The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1196-1207.	3.4	83
17	Strong Association between Gallstones and Cardiovascular Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 827-830.	0.4	77
18	Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. <i>Journal of Hepatology</i> , 2008, 48, 116-124.	3.7	77

#	ARTICLE	IF	CITATIONS
19	Etiology of Liver Cirrhosis in Mexico. <i>Annals of Hepatology</i> , 2004, 3, 30-33.	1.5	76
20	In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. <i>Journal of Hepatology</i> , 2010, 53, 732-737.	3.7	74
21	Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. <i>Liver International</i> , 2007, 27, 215-219.	3.9	72
22	High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. <i>Annals of Hepatology</i> , 2012, 11, 350-355.	1.5	71
23	Role of diet in cholesterol gallstone formation. <i>Clinica Chimica Acta</i> , 2007, 376, 1-8.	1.1	66
24	The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2015, 14, 487-493.	1.5	65
25	Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. <i>BMC Cancer</i> , 2005, 5, 142.	2.6	63
26	Pregnancy and gallbladder disease. <i>Annals of Hepatology</i> , 2006, 5, 227-230.	1.5	61
27	Eosinophilic Gastroenteritis: A Review. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2904-2911.	2.3	61
28	Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. <i>World Journal of Gastroenterology</i> , 2008, 14, 4771.	3.3	61
29	Beneficial Effect of Vegetable Protein Diet Supplemented With Psyllium Plantago in Patients With Hepatic Encephalopathy and Diabetes Mellitus. <i>Gastroenterology</i> , 1985, 88, 901-907.	1.3	60
30	Anabolic androgenic steroids and liver injury. <i>Liver International</i> , 2008, 28, 278-282.	3.9	58
31	Transcript levels of Toll-Like receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative Colitis. <i>BMC Gastroenterology</i> , 2011, 11, 138.	2.0	58
32	Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. <i>Annals of Hepatology</i> , 2004, 3, 108-112.	1.5	55
33	The prevalence of nonalcoholic fatty liver disease in the Americas. <i>Annals of Hepatology</i> , 2014, 13, 166-78.	1.5	55
34	Image-guided percutaneous procedure plus metronidazole versus metronidazole alone for uncomplicated amoebic liver abscess. <i>The Cochrane Library</i> , 2009, , CD004886.	2.8	53
35	The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH. <i>Toxicology in Vitro</i> , 2015, 29, 1753-1758.	2.4	49
36	Association between cholecystectomy for gallstone disease and risk factors for cardiovascular disease. <i>Annals of Hepatology</i> , 2012, 11, 85-89.	1.5	48

#	ARTICLE	IF	CITATIONS
37	Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. <i>Hepatology Research</i> , 2014, 44, E92-9.	3.4	48
38	Prevalence of gallstone disease in Mexico. <i>Digestive Diseases and Sciences</i> , 1993, 38, 680-683.	2.3	46
39	Herbal Medicine in Mexico: A Cause of Hepatotoxicity. A Critical Review. <i>International Journal of Molecular Sciences</i> , 2016, 17, 235.	4.1	46
40	Prophylactic Activated Recombinant Factor VII in Liver Resection and Liver Transplantation: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e22581.	2.5	42
41	Adiponectin as a protective factor in hepatic steatosis. <i>World Journal of Gastroenterology</i> , 2005, 11, 1737.	3.3	40
42	Fish Oil (n-3) Polyunsaturated Fatty Acids Beneficially Affect Biliary Cholesterol Nucleation Time in Obese Women Losing Weight. <i>Journal of Nutrition</i> , 2001, 131, 2300-2303.	2.9	39
43	Prevalence of Hepatitis C Virus Infection among Hemodialysis Patients at a Tertiary-Care Hospital in Mexico City, Mexico. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4321-4322.	3.9	39
44	The Amerindian's Genes in the Mexican Population are Associated with Development of Gallstone Disease. <i>American Journal of Gastroenterology</i> , 2004, 99, 2166-2170.	0.4	39
45	High ghrelin and obestatin levels and low risk of developing fatty liver. <i>Annals of Hepatology</i> , 2010, 9, 52-57.	1.5	35
46	Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2014, 13, S4-S40.	1.5	34
47	Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2008, 7, 67-71.	1.5	33
48	Diagnostic accuracy of nodular gastritis for H. pylori infection. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 13, 9-14.	2.0	33
49	Association Among C-Reactive Protein, Fatty Liver Disease, and Cardiovascular Risk. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2375-2379.	2.3	32
50	Biomarkers in hepatocellular carcinoma: an overview. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 549-558.	3.0	31
51	The role of the gut microbiota in the pathology and prevention of liver disease. <i>Journal of Nutritional Biochemistry</i> , 2018, 60, 1-8.	4.2	31
52	Common Features of the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. <i>Reviews on Recent Clinical Trials</i> , 2015, 9, 148-158.	0.8	31
53	Nuclear Receptors in Nonalcoholic Fatty Liver Disease. <i>Journal of Lipids</i> , 2012, 2012, 1-10.	4.8	30
54	The Role of Dendritic Cells in Fibrosis Progression in Nonalcoholic Fatty Liver Disease. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	29

#	ARTICLE	IF	CITATIONS
55	Current evidence on the use of probiotics in liver diseases. <i>Journal of Functional Foods</i> , 2015, 17, 137-151.	3.4	29
56	Endoscopic submucosal dissection in dogs in a World Gastroenterology Organisation training center. <i>World Journal of Gastroenterology</i> , 2010, 16, 1759.	3.3	29
57	Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, S4-S66.	1.5	28
58	Serum Zinc Concentrations in Two Cohorts of 153 Healthy Subjects and 100 Cirrhotic Patients from Mexico City. <i>Digestive Diseases</i> , 1995, 13, 136-142.	1.9	27
59	Gallstones are associated with carotid atherosclerosis. <i>Liver International</i> , 2008, 28, 402-406.	3.9	27
60	Liver diseases in Mexico and their associated mortality trends from 2000 to 2007: A retrospective study of the nation and the federal states. <i>Annals of Hepatology</i> , 2010, 9, 428-438.	1.5	27
61	Mitochondrial Molecular Pathophysiology of Nonalcoholic Fatty Liver Disease: A Proteomics Approach. <i>International Journal of Molecular Sciences</i> , 2016, 17, 281.	4.1	26
62	Less liver fibrosis in metabolically healthy compared with metabolically unhealthy obese patients with non-alcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , 2017, 43, 332-337.	2.9	25
63	Hepatic manifestations of metabolic syndrome. <i>Diabetes/Metabolism Research and Reviews</i> , 2013, , .	4.0	24
64	Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 194, 105445.	2.5	24
65	Risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care hospital in Mexico City, Mexico: a descriptive study. <i>Annals of Hepatology</i> , 2006, 5, 276-280.	1.5	23
66	Treating nonalcoholic fatty liver disease. <i>Liver International</i> , 2007, 27, 070901081846003-???	3.9	23
67	Hepatobiliary Diseases and Insulin Resistance. <i>Current Medicinal Chemistry</i> , 2007, 14, 1988-1999.	2.4	22
68	Adiponectin, Structure, Function and Pathophysiological Implications in Non-Alcoholic Fatty Liver Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , 2006, 6, 651-656.	2.4	21
69	Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure. <i>Annals of Hepatology</i> , 2011, 10, S70-S76.	1.5	21
70	Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review. <i>World Journal of Gastroenterology</i> , 2006, 12, 7826.	3.3	21
71	Research Communication: Plasma Leptin and the Cholesterol Saturation of Bile Are Correlated in Obese Women after Weight Loss. <i>Journal of Nutrition</i> , 2002, 132, 2195-2198.	2.9	20
72	Serum leptin levels and insulin resistance are associated with gallstone disease in overweight subjects. <i>World Journal of Gastroenterology</i> , 2005, 11, 6182.	3.3	20

#	ARTICLE	IF	CITATIONS
73	New insights into the pathophysiology of nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2009, 8, S9-S17.	1.5	19
74	Risk factors for gallstone disease in Mexicans are similar to those found in Mexican-Americans. <i>Digestive Diseases and Sciences</i> , 1998, 43, 935-939.	2.3	18
75	Learning Curve in a Western Training Center of the Circumferential En Bloc Esophageal Endoscopic Submucosal Dissection in an In Vivo Animal Model. <i>Diagnostic and Therapeutic Endoscopy</i> , 2011, 2011, 1-8.	1.5	18
76	Role of the inflammasome, gasdermin D, and pyroptosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2720-2727.	2.8	18
77	Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?. <i>World Journal of Gastroenterology</i> , 2016, 22, 6965.	3.3	18
78	The Molecular Basis of Susceptibility to Infection in Liver Cirrhosis. <i>Current Medicinal Chemistry</i> , 2007, 14, 2954-2958.	2.4	17
79	Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. <i>Annals of Hepatology</i> , 2005, 4, 52-5.	1.5	17
80	TLR9 mRNA expression is upregulated in patients with active ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1267-1268.	1.9	16
81	Elevated cholesterol levels have a poor prognosis in a cholestasis scenario. <i>Journal of Biochemical and Molecular Toxicology</i> , 2017, 31, 1-6.	3.0	16
82	Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis. <i>Alcohol</i> , 2018, 69, 63-67.	1.7	16
83	The Efficacy of Adipokines and Indices of Metabolic Syndrome as Predictors of Severe Obesity-Related Hepatic Steatosis. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1716-1722.	2.3	15
84	Role of nonalcoholic fatty liver disease in hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2009, 8, S34-S39.	1.5	15
85	Factors Associated with the Quality of Transient Elastography. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2177-2182.	2.3	15
86	Etiology of liver cirrhosis in Mexico. <i>Annals of Hepatology</i> , 2004, 3, 30-3.	1.5	15
87	Microscopic colitides: a single center experience in Mexico. <i>International Journal of Colorectal Disease</i> , 2007, 22, 1031-1036.	2.2	14
88	Prevalence of type 2 diabetes mellitus and chronic liver disease: A retrospective study of the association of two increasingly common diseases in Mexico. <i>Annals of Hepatology</i> , 2010, 9, 282-288.	1.5	14
89	IFN-stimulated Gene Expression Is a Useful Potential Molecular Marker of Response to Antiviral Treatment with Peg-IFN α 2b and Ribavirin in Patients with Hepatitis C Virus Genotype 1. <i>Archives of Medical Research</i> , 2011, 42, 28-33.	3.3	14
90	The role of dietary fats in the pathogenesis of gallstones. <i>Frontiers in Bioscience - Landmark</i> , 2003, 8, e420-427.	3.0	14

#	ARTICLE	IF	CITATIONS
91	Prevalence of Hepatitis C Infection in a Population of Asymptomatic People in a Checkup Unit in Mexico City. <i>Digestive Diseases and Sciences</i> , 2005, 50, 733-737.	2.3	13
92	Geographical distribution of HCV genotypes in Mexico. <i>Annals of Hepatology</i> , 2007, 6, 156-160.	1.5	13
93	Hypoxic hepatitis in cardiac intensive care unit: a study of cardiovascular risk factors, clinical course, and outcomes. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 139.	2.0	13
94	Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America. <i>Annals of Hepatology</i> , 2015, 14, 807-814.	1.5	13
95	Liver toxicity mechanisms of herbs commonly used in Latin America. <i>Drug Metabolism Reviews</i> , 2017, 49, 338-356.	3.6	13
96	Association Between Serum Hemoglobin Levels and Non Alcoholic Fatty Liver Disease in a Mexican Population. <i>Annals of Hepatology</i> , 2018, 17, 577-584.	1.5	13
97	The Management of Incidental Fatty Liver Found on Imaging. What Do We Need to do?. <i>American Journal of Gastroenterology</i> , 2018, 113, 1274-1276.	0.4	12
98	Manipulation of microbiota with probiotics as an alternative for treatment of hepatic encephalopathy. <i>Nutrition</i> , 2020, 73, 110693.	2.4	12
99	Low serum levels of ghrelin are associated with gallstone disease. <i>World Journal of Gastroenterology</i> , 2006, 12, 3096.	3.3	12
100	Obesity-related leptin receptor polymorphisms and gallstones disease. <i>Annals of Hepatology</i> , 2006, 5, 97-102.	1.5	11
101	High Gene Expression of MDR1 (ABCB1) is Associated with Medical Treatment Response and Long-Term Remission in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 541-542.	1.9	11
102	Impact of anthropometric cut-off values in determining the prevalence of metabolic alterations. <i>European Journal of Clinical Investigation</i> , 2016, 46, 940-946.	3.4	11
103	The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease. <i>Annals of Internal Medicine</i> , 2006, 144, 379.	3.9	10
104	The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , 2015, 15, 1187-1194.	2.4	10
105	Effects of Leptin on Biliary Lipids: Potential Consequences for Gallstone Formation and Therapy in Obesity. <i>Current Drug Targets Immune, Endocrine and Metabolic Disorders</i> , 2005, 5, 203-208.	1.8	9
106	Metabolic syndrome and nonalcoholic fatty liver disease. The role of endothelial progenitor cells TM . <i>Annals of Hepatology</i> , 2013, 12, 908-914.	1.5	9
107	An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver. <i>Annals of Hepatology</i> , 2013, 12, S3-S35.	1.5	9
108	Cholecystectomy as a risk factor for non-alcoholic fatty liver disease development. <i>Hpb</i> , 2020, 22, 1513-1520.	0.3	9

#	ARTICLE	IF	CITATIONS
109	Non-Alcoholic Fatty-Liver Disease in Pediatric Populations. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2007, 20, 1059-73.	0.9	8
110	Importance of Iron and Iron Metabolism in Nonalcoholic Fatty Liver Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 171-174.	2.4	8
111	A Genetic Variant in the Interleukin 28B Gene As a Major Predictor for Sustained Virologic Response in Chronic Hepatitis C Virus Infection. <i>Archives of Medical Research</i> , 2015, 46, 448-453.	3.3	8
112	Factors that influence outcome in non-invasive and invasive treatment in polycystic liver disease patients. <i>World Journal of Gastroenterology</i> , 2008, 14, 3195.	3.3	8
113	The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2019, 12, 267-277.	0.6	8
114	Clinical heterogeneity in autoimmune acute liver failure. <i>World Journal of Gastroenterology</i> , 2007, 13, 1824.	3.3	7
115	Validation of prognostic scores for clinical outcomes in cirrhotic patients with acute variceal bleeding. <i>Annals of Hepatology</i> , 2016, 15, 895-901.	1.5	7
116	Renovation of <i>Annals of Hepatology</i> 's Scientific Scope: Towards Preventing Rather Than Treating End-Stage Liver Disease. <i>Annals of Hepatology</i> , 2018, 17, 539-540.	1.5	6
117	Dietary consumption and serum pattern of bioactive fatty acids in NAFLD patients. <i>Annals of Hepatology</i> , 2020, 19, 482-488.	1.5	6
118	G protein-coupled receptors: Key molecules in metabolic associated fatty liver disease development. <i>Nutrition Research</i> , 2021, 87, 70-79.	2.9	6
119	Evaluation of Iron Overload in Healthy Adult Residents of Mexico City. <i>Archives of Medical Research</i> , 2005, 36, 142-147.	3.3	5
120	Human leukocyte antigens among primary biliary cirrhosis patients born in Mexico. <i>Annals of Hepatology</i> , 2009, 8, 32-37.	1.5	5
121	Bile acids and the risk for hepatocellular carcinoma in primary biliary cholangitis. <i>Annals of Hepatology</i> , 2016, 15, 453-454.	1.5	5
122	Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure. <i>Annals of Hepatology</i> , 2011, 10 Suppl 2, S70-6.	1.5	5
123	The utility of the 13 C-methacetin breath test in predicting the long-term survival of patients with decompensated cirrhosis. <i>Journal of Breath Research</i> , 2017, 11, 036011.	3.0	4
124	A New Stage in <i>Annals of Hepatology</i> . <i>Annals of Hepatology</i> , 2018, 17, 339-340.	1.5	4
125	Cerebral hemodynamics in the non-alcoholic fatty liver. <i>Annals of Hepatology</i> , 2020, 19, 668-673.	1.5	4
126	Metabolic Features of Alcoholic Liver Disease. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 220-226.	0.8	4

#	ARTICLE	IF	CITATIONS
127	Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis. <i>Annals of Hepatology</i> , 2022, 27, 100651.	1.5	4
128	Response to Letter of Guy D. Eslick. <i>American Journal of Gastroenterology</i> , 2005, 100, 2363-2363.	0.4	3
129	Metabolic syndrome and estimates of cardiovascular disease in cirrhotic patients. <i>Journal of Digestive Diseases</i> , 2008, 9, 149-155.	1.5	3
130	Latin American Association for the Study of the Liver Practice Guidelines. <i>Annals of Hepatology</i> , 2010, 9, S8-S26.	1.5	3
131	New strategies for treating hepatic encephalopathy. <i>Annals of Hepatology</i> , 2014, 13, 409-411.	1.5	3
132	Prevalence in vulnerable population of liver fibrosis identified by transient elastography. <i>Annals of Hepatology</i> , 2015, 14, 524-530.	1.5	3
133	Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico. <i>Clinical Liver Disease</i> , 2022, 19, 68-72.	2.1	3
134	Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report. <i>Annals of Hepatology</i> , 2003, 2, 183-185.	1.5	2
135	Atorvastatin and portal pressure. <i>Hepatology</i> , 2007, 46, 1309-1310.	7.3	2
136	Hepatocyte transplantation for treating chronic hepatic dysfunction. <i>Journal of Organ Dysfunction</i> , 2007, 3, 131-136.	0.3	1
137	Nonalcoholic steatohepatitis in chronic hepatitis C: A new classification?. <i>Hepatology</i> , 2007, 47, 759-759.	7.3	1
138	Assessment of Outcomes of Hepatitis C Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2570.	7.4	1
139	Bioactive lipids in metabolic liver disease. <i>Studies in Natural Products Chemistry</i> , 2021, , 263-297.	1.8	1
140	Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report. <i>Annals of Hepatology</i> , 2003, 2, 183-5.	1.5	1
141	Food for Liver Health: Probiotics. , 2019, , 387-391.		0